Search

State-of-the-art facility will be reduced by 76 feet while continuing to meet increasing demand for cancer care.

… Friday, May 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced an updated design for MSK’s forthcoming Kenneth C. Griffin Pavilion at MSK, which includes a reduction in the originally proposed height of the building by 76 feet. The newly-designed Griffin Pavilion, slated for construction

Learn about the latest advances in lung cancer treatment at MSK.

… Friday, November 15, 2024 Lung cancer is the second-most common cancer and remains the leading cause of cancer death in the United States. But a variety of new treatments, many of them developed or tested at Memorial Sloan Kettering Cancer Center (MSK), are helping to bring down the number of deaths.

Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.

… Friday, November 15, 2024 El cáncer pulmonar es el segundo cáncer más común y sigue siendo la principal causa de muerte por cáncer en los Estados Unidos. Sin embargo, una variedad de nuevos tratamientos, muchos de ellos desarrollados o probados en el Memorial Sloan Kettering Cancer Center (MSK), están

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

… Saturday, January 1, 2011 Summary To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. The goal of the new

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

… Thursday, September 11, 2025 A high-intensity radiation beam that penetrates the body to burn away tumors has been a standard weapon against cancer for more than a century. Over the years, radiation therapy has improved dramatically, but its effectiveness against cancers in multiple places can be limited

Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).

… Wednesday, December 7, 2022 Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University

Learn about the goals of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research: to reveal more about the biology of lung cancer, to examine novel treatment approaches, and to bring promising new therapies to our patients.

… Thursday, October 1, 2020 Lung cancer causes more deaths in the United States than colon, breast, and prostate cancers combined. Memorial Sloan Kettering launched the Fiona and Stanley Druckenmiller Center for Lung Cancer Research (DCLCR) in 2015 with three primary goals: to reveal more about the biology

Meet three people who were treated as part of a clinical trial for melanoma at Memorial Sloan Kettering.

… Wednesday, February 7, 2018 Summary Behind the incredible discoveries that happen in MSK labs are the equally incredible patients who walk through our doors and bring the science to life. Here, meet three MSK patients who took part in a clinical trial led by surgeon Charlotte Ariyan for the treatment

The global prize is awarded annually to a researcher, physician, or team leader who has made a positive and lasting impact in the fight against pediatric cancer.

… Thursday, May 20, 2021 Memorial Sloan Kettering Cancer Center (MSK) announced that pediatric oncologist A. Thomas Look, MD , of the Dana-Farber / Boston Children’s Cancer and Blood Disorder Center has been named the 2021 recipient of The Society of Memorial Sloan Kettering Prize . The award was presented

With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center.

… Monday, June 21, 2021 With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center. In the midst of a global pandemic, Cycle for Survival , the movement to beat rare cancers, raised $25